|
1
|
Global status report on noncommunicable
diseases 2014. World Health Organization; Geneva: pp. 11–14.
2014
|
|
2
|
Cancer Facts & Figures 2014. American
Cancer Society; Atlanta, GA: pp. 14–15. 2014
|
|
3
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
Classification of Lung Tumors: Impact of Genetic, Clinical and
Radiologic Advances Since the 2004 Classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Santana-Davila R and Martins R: Treatment
of stage IIIA non-small-cell lung cancer: A concise review for the
practicing oncologist. J Oncol Pract. 12:601–606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katayama R, Shaw AT, Khan TM,
Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT,
Benes C, et al: Mechanisms of acquired crizotinib resistance in
ALK-rearranged lung Cancers. Sci Transl Med. 4:120ra172012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:pp.
584–594. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Butts C, Socinski MA, Mitchell PL,
Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée
L, Trigo JM, et al: Tecemotide (L-BLP25) versus placebo after
chemoradiotherapy for stage III non-small-cell lung cancer (START):
A randomized, double-blind, phase 3 trial. Lancet Oncol. 15:59–68.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dessureault S, Noyes D, Lee D, Dunn M,
Janssen W, Cantor A, Sotomayor E, Messina J and Antonia SJ: A
phase-I trial using a universal GM-CSF-producing and
CD40L-expressing bystander cell line (GM.CD40L) in the formulation
of autologous tumor cell-based vaccines for cancer patients with
stage IV disease. Ann Surg Oncol. 14:869–884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nemunaitis J, Nemunaitis M, Senzer N,
Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D and
Fakhrai H: Phase II trial of Belagenpumatucel-L, a TGF-beta2
antisense gene modified allogeneic tumor vaccine in advanced non
small cell lung cancer (NSCLC) patients. Cancer Gene Ther.
16:620–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Palmer M, Parker J, Modi S, Butts C,
Smylie M, Meikle A, Kehoe M, MacLean G and Longenecker M: Phase I
study of the BLP25 (MUC1 peptide) liposomal vaccine for active
specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.
Clin Lung Cancer. 3:49–58. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quoix E, Ramlau R, Westeel V, Papai Z,
Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun
D, et al: Therapeutic vaccination with TG4010 and first-line
chemotherapy in advanced non-small-cell lung cancer: A controlled
phase 2B trial. Lancet Oncol. 12:1125–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang N, Zhong WZ and Wu YL: Special issue
on personalized therapy in lung cancer. Transl Lung Cancer Res.
3:358–359. 2014.PubMed/NCBI
|
|
15
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hayama S, Daigo Y, Kato T, Ishikawa N,
Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y:
Activation of CDCA1-KNTC2, members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ishikawa N, Takano A, Yasui W, Inai K,
Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, et
al: Cancer-testis antigen lymphocyte antigen 6 complex locus K is a
serologic biomarker and a therapeutic target for lung and
esophageal carcinomas. Cancer Res. 67:11601–11611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tomita Y, Harao M, Senju S, Imai K, Hirata
S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, et al:
Peptides derived from human insulin-like growth factor-II mRNA
binding protein 3 can induce human leukocyte antigen-A2-restricted
cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci.
102:71–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kono K, Mizukami Y, Daigo Y, Takano A,
Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y and Fujii
H: Vaccination with multiple peptides derived from novel
cancer-testis antigens can induce specific T-cell responses and
clinical responses in advanced esophageal cancer. Cancer Sci.
100:1502–1509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshitake Y, Fukuma D, Yuno A, Hirayama M,
Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y,
et al: Phase II clinical trial of multiple peptide vaccination for
advanced head and neck cancer patients revealed induction of immune
responses and improved OS. Clin Cancer Res. 21:312–321. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harrop R: Cancer vaccines: Identification
of biomarkers predictive of clinical efficacy. Hum Vaccin
Immunother. 9:800–804. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang H, Yamaguchi R, Liu X, Daigo Y, Yew
PY, Tanikawa C, Matsuda K, Imoto S, Miyano S and Nakamura Y:
Quantitative T cell repertoire analysis by deep cDNA sequencing of
T cell receptor α and β chains using next-generation sequencing
(NGS). Oncoimmunology. 3:e9684672015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong AK and Walkey AJ: Open lung biopsy
among critically Ill, mechanically ventilated patients: A
Metaanalysis. Ann Am Thorac Soc. 12:1226–1230. 2015.PubMed/NCBI
|
|
27
|
Mehta S, Shelling A, Muthukaruppan A,
Lasham A, Blenkiron C, Laking G and Print C: Predictive and
prognostic molecular markers for cancer medicine. Ther Adv Med
Oncol. 2:125–148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang
G, Wu L and Jiao S: Adoptive immunotherapy for non-small cell lung
cancer by NK and cytotoxic T lymphocytes mixed effector cells:
Retrospective clinical observation. Int Immunopharmacology.
21:396–405. 2014. View Article : Google Scholar
|
|
29
|
Santegoets SJ, Turksma AW, Suhoski MM,
Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ,
Gerritsen WR, Powell DJ Jr, et al: IL-21 promotes the expansion of
CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic
potential and low collateral expansion of regulatory T cells. J
Transl Med. 11:372013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khazaie K and von Boehmer H: The impact of
CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and
cancer. Semin Cancer Biol. 16:124–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Erfani N, Mehrabadi SM, Ghayumi MA,
Haghshenas MR, Mojtahedi Z, Ghaderi A and Amani D: Increase of
regulatory T cells in metastatic stage and CTLA-4 over expression
in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Lung Cancer. 77:306–311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Phillips JD, Knab LM, Blatner NR, Haghi L,
DeCamp MM, Meyerson SL, Heiferman MJ, Heiferman JR, Gounari F,
Bentrem DJ and Khazaie K: Preferential expansion of
pro-inflammatory Tregs in human non-small cell lung cancer. Cancer
Immunol Immunother. 64:1185–1191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gounaris E, Blatner NR, Dennis K,
Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F and Khazaie
K: T-regulatory cells shift from a protective anti-inflammatory to
a cancer-promoting proinflammatory phenotype in polyposis. Cancer
Res. 69:5490–5497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Glusman G, Rowen L, Lee I, Boysen C, Roach
JC, Smit AF, Wang K, Koop BF and Hood L: Comparative genomics of
the human and mouse T cell receptor loci. Immunity. 15:337–349.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Litman GW, Rast JP and Fugmann SD: The
origins of vertebrate adaptive immunity. Nat Rev Immunol.
10:543–553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Folch G and Lefranc MP: The human T cell
receptor beta variable (TRBV) genes. Exp Clin Immunogenet.
17:42–54. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Haynes MR and Wu GE: Gene discovery at the
human T-cell receptor alpha/delta locus. Immunogenetics.
59:109–121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scaviner D and Lefranc MP: The human T
cell receptor alpha variable (TRAV) genes. Exp Clin Immunogenet.
17:83–96. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robinson MW, Hughes J, Wilkie GS, Swann R,
Barclay ST, Mills PR, Patel AH, Thomson EC and McLauchlan J:
Tracking TCRβ sequence clonotype expansions during antiviral
therapy using high-throughput sequencing of the hypervariable
region. Front Immunol. 7:1312016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Britanova OV, Putintseva EV, Shugay M,
Merzlyak EM, Turchaninova MA, Staroverov DB, Bolotin DA, Lukyanov
S, Bogdanova EA, Mamedov IZ, et al: Age-related decrease in TCR
repertoire diversity measured with deep and normalized sequence
profiling. J Immunol. 192:2689–2698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Z, Liu G, Tong Y, Zhang M, Xu Y, Qin L,
Wang Z, Chen X and He J: Comprehensive analysis of the T-cell
receptor beta chain gene in rhesus monkey by high throughput
sequencing. Sci Rep. 5:100922015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li D, Gao G, Li Z, Sun W, Li X, Chen N,
Sun J and Yang Y: Profiling the T-cell receptor repertoire of
patient with pleural tuberculosis by high-throughput sequencing.
Immunol Lett. 162:170–180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yew PY, Alachkar H, Yamaguchi R, Kiyotani
K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, et al:
Quantitative characterization of T-cell repertoire in allogeneic
hematopoietic stem cell transplant recipients. Bone Marrow
Transplant. 50:1227–1234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giudicelli V, Chaume D and Lefranc MP:
IMGT/GENE-DB: A comprehensive database for human and mouse
immunoglobulin and T cell receptor genes. Nucleic Acids Res.
33(Database Issue): D256–D261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Spiotto MT and Schreiber H: Rapid
destruction of the tumor microenvironment by CTLs recognizing
cancer-specific antigens cross-presented by stromal cells. Cancer
Immun. 5:82005.PubMed/NCBI
|
|
47
|
Bonmassar E, Bonmassar A, Vadlamudi S and
Goldin A: Immunological alteration of leukemic cells in vivo after
treatment with an antitumor drug. Proc Natl Acad Sci USA. 66:pp.
1089–1095. 1970; View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Speiser DE, Baumgaertner P, Barbey C,
Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY,
Rimoldi D, Liénard D, et al: A novel approach to characterize
clonality and differentiation of human melanoma-specific T cell
responses: Spontaneous priming and efficient boosting by
vaccination. J Immunol. 177:1338–1348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Palermo B, Del Bello D, Sottini A, Serana
F, Ghidini C, Gualtieri N, Ferraresi V, Catricalà C, Belardelli F,
Proietti E, et al: Dacarbazine treatment before peptide vaccination
enlarges T-cell repertoire diversity of melan-a-specific,
tumor-reactive CTL in melanoma patients. Cancer Res. 70:7084–7092.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cornberg M, Chen AT, Wilkinson LA, Brehm
MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM and
Selin LK: Narrowed TCR repertoire and viral escape as a consequence
of heterologous immunity. J Clin Invest. 116:1443–1456. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reis DD, Jones EM, Tostes S Jr, Lopes ER,
Gazzinelli G, Colley DG and McCurley TL: Characterization of
inflammatory infiltrates in chronic chagasic myocardial lesions:
Presence of tumor necrosis factor-alpha+ cells and dominance of
granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg. 48:637–644. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen RH, Ivens KW, Alpert S, Billingham
ME, Fathman CG, Flavin TF, Shizuru JA, Starnes VA, Weissman IL and
Griffiths GM: The use of granzyme A as a marker of heart transplant
rejection in cyclosporine or anti-CD4 monoclonal antibody-treated
rats. Transplantation. 55:146–153. 1993. View Article : Google Scholar : PubMed/NCBI
|
